SEARCH

SEARCH BY CITATION

References

  • 1
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 2
    Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn’s Colitis 2010; 4: S56.
  • 3
    Hinojosa J, Gomollón F, García S, et al. Efficacy and safety of short-term Adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 40918.
  • 4
    Teshima CW, Thompson A, Dhanoa L, et al. Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 34852.
  • 5
    Chowers Y, Allez M. Efficacy of anti-TNF in Crohn’s disease: how does it work? Curr Drug Targets 2010; 11: 13842.
  • 6
    Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118: S28.
  • 7
    Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 8
    Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 9
    Afif W, Leighton JA, Hanauer SB, et al. Open-label study of Adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 13027.
  • 10
    Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 232832.
  • 11
    Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28: 96672.
  • 12
    Hudis N, Rajca B, Polyak S, et al. The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology 2009; 136: A-683.
  • 13
    Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn’s Colitis 2008; 2: 21925.
  • 14
    Senent S, Martín-Arranz M, Merino L, et al. Infliximab in ulcerative colitis: concomitant cytomegalovirus infection, Lifes Quality, PPD positive have an influence on the treatment with infliximab. Gastroenterology 2009; 136: A-682.
  • 15
    Jürgens M, Brand S, Laubender R, et al. Disease activity and pANCA status determine early response to infliximab in ulcerative colitis. Gastroenterology 2009; 136: A-680.
  • 16
    Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 21026.
  • 17
    Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 125060.